Sneaky Delivery System Revolutionizes Multiple Sclerosis Treatment

By Maxx Chatsko | More Articles June 25, 2013 |

Multiple sclerosis, or MS, is an autoimmune disorder in which the immune system attacks myelin surrounding nerves. It is a debilitating disease with no cure. Luckily, as our understanding of triggers in the immune system deepens, so does the likelihood of developing more effective treatments or even a cure. A new study shows just how far we have come.

A team of scientists from Northwestern University, University Hospital Zurich in Switzerland, and University Medical Center Hamburg-Eppendorf in Germany demonstrated that resetting a patient's immune system was safe and reduced the targeting of myelin by 50%-75%. The phase 1 trial supported moving into a phase 2 trial in Switzerland after funds are raised. It is great news for patients and will likely revolutionize the way we treat autoimmune diseases and allergy medications. However, it will be a long time before it readily competes with Gilenya from Novartis (NYSE: NVS) . Fool contributor Maxx Chatsko breaks it down for investors in the following video.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of.Click here nowto keep reading.

Go here to see the original:
Sneaky Delivery System Revolutionizes Multiple Sclerosis Treatment